eculizumab (Soliris) Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive.
eculizumab (Soliris) For treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.
eculizumab (Soliris) aHUS in adults and children for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS).
eculizumab (Soliris) for PNH Treatment of children and adults with paroxysmal nocturnal haemoglobinuria (PNH)
ravulizumab (Ultomiris) For the treatment of patients with a body weight of 10kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
danicopan (Voydeya) As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.
ravulizumab (Ultomiris) For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):• in patients with haemolysis with clinical symptom(s) indicative of high disease activity• in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.
February 2016 decisions news release The Scottish Medicines Consortium (SMC) has announced today that it has accepted five new medicines for routine use by NHSScotland.
April 2016 decisions news release The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today published advice accepting three new medicines for routine use by NHSScotland.
